Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | CD37 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C4660H7136N1246O1452S30 |
Molar mass | 104809.42 g·mol−1 |
Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37 [1] designed for the treatment of cancer. [2]
This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL) [3]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | CD37 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C4660H7136N1246O1452S30 |
Molar mass | 104809.42 g·mol−1 |
Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37 [1] designed for the treatment of cancer. [2]
This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL) [3]